Cellectis (CLLS) Revenue & Revenue Breakdown
Cellectis Revenue Highlights
Latest Revenue (Y)
$755.00K
Latest Revenue (Q)
$4.53M
Main Segment (Y)
Therapeutics
Main Geography (Y)
FRANCE
Cellectis Revenue by Period
Cellectis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $755.00K | -96.06% |
| 2022-12-31 | $19.17M | -74.08% |
| 2021-12-31 | $73.95M | - |
| 2020-12-31 | $73.95M | 386.83% |
| 2019-12-31 | $15.19M | 19.32% |
| 2018-12-31 | $12.73M | -49.46% |
| 2017-12-31 | $25.19M | -40.85% |
| 2016-12-31 | $42.58M | -22.63% |
| 2015-12-31 | $55.04M | 109.30% |
| 2014-12-31 | $26.30M | 15.26% |
| 2013-12-31 | $22.82M | -17.97% |
| 2012-12-31 | $27.81M | 34.19% |
| 2011-12-31 | $20.73M | -1.20% |
| 2010-12-31 | $20.98M | 21.14% |
| 2009-12-31 | $17.32M | 17.26% |
| 2008-12-31 | $14.77M | 260.13% |
| 2007-12-31 | $4.10M | - |
Cellectis generated $755.00K in revenue during NA 2023, up -96.06% compared to the previous quarter, and up 5.93% compared to the same period a year ago.
Cellectis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $4.53M | 1500.00% |
| 2023-12-31 | $283.00K | 82.58% |
| 2023-09-30 | $155.00K | -12.92% |
| 2023-06-30 | $178.00K | 28.06% |
| 2023-03-31 | $139.00K | -99.13% |
| 2022-12-31 | $16.02M | 7284.33% |
| 2022-09-30 | $217.00K | -83.90% |
| 2022-06-30 | $1.35M | -20.57% |
| 2022-03-31 | $1.70M | -87.57% |
| 2021-12-31 | $13.65M | 64.21% |
| 2021-09-30 | $8.31M | -25.63% |
| 2021-06-30 | $11.18M | -56.35% |
| 2021-03-31 | $25.60M | 87.57% |
| 2020-12-31 | $13.65M | 120.86% |
| 2020-09-30 | $6.18M | 113.10% |
| 2020-06-30 | $2.90M | -94.21% |
| 2020-03-31 | $50.13M | 1033.37% |
| 2019-12-31 | $4.42M | -47.89% |
| 2019-09-30 | $8.49M | 636.81% |
| 2019-06-30 | $1.15M | 11.20% |
| 2019-03-31 | $1.04M | 7.02% |
| 2018-12-31 | $968.00K | 6.96% |
| 2018-09-30 | $905.00K | -82.08% |
| 2018-06-30 | $5.05M | -16.41% |
| 2018-03-31 | $6.04M | 5.50% |
| 2017-12-31 | $5.72M | -6.48% |
| 2017-09-30 | $6.12M | -9.32% |
| 2017-06-30 | $6.75M | -0.16% |
| 2017-03-31 | $6.76M | -15.39% |
| 2016-12-31 | $7.99M | -29.41% |
| 2016-09-30 | $11.32M | -35.68% |
| 2016-06-30 | $17.60M | 122.57% |
| 2016-03-31 | $7.91M | -72.51% |
| 2015-12-31 | $28.76M | 236.35% |
| 2015-09-30 | $8.55M | 4.04% |
| 2015-06-30 | $8.22M | 100.00% |
| 2014-06-30 | - | - |
Cellectis generated $4.53M in revenue during Q1 2024, up 1500.00% compared to the previous quarter, and up 28.26% compared to the same period a year ago.
Cellectis Revenue Breakdown
Cellectis Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|
| Therapeutics | $25.73M | - | - | - |
| High Oleic Soyabean Oil | - | $27.00M | $22.90M | $1.70M |
| ALLO715 | - | - | $28.50M | $5.00M |
| High Oleic Soyabean Meal | - | - | - | $5.60M |
Cellectis's latest annual revenue breakdown by segment (product or service), as of Dec 22: Therapeutics (100.00%).
Cellectis Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | - | - | $26.95M | $22.89M | $7.29M |
| FRANCE | $755.00K | $19.17M | $30.35M | $51.06M | $7.90M |
Cellectis's latest annual revenue breakdown by geography, as of Dec 23: FRANCE (100.00%).
Cellectis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RGNX | REGENXBIO | $90.24M | $22.30M |
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| NRIX | Nurix Therapeutics | $76.99M | $12.59M |
| IPHA | Innate Pharma | $51.90M | $16.56M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| GNFT | Genfit | $28.57M | $17.08M |
| SGTX | Sigilon Therapeutics | $12.94M | $5.90M |
| KZR | Kezar Life Sciences | $7.00M | - |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| INBX | Inhibrx Biosciences | $1.80M | - |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| CLLS | Cellectis | $755.00K | $4.53M |
| ANEB | Anebulo Pharmaceuticals | - | - |
| LIAN | LianBio | - | - |
| SLNO | Soleno Therapeutics | - | - |
| DMAC | DiaMedica Therapeutics | - | - |
| CYT | Cyteir Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| ELYM | Eliem Therapeutics | - | - |
| ERYP | PHAXIAM Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
CLLS Revenue FAQ
What is Cellectis’s yearly revenue?
Cellectis's yearly revenue for 2023 was $755K, representing a decrease of -96.06% compared to 2022. The company's yearly revenue for 2022 was $19.17M, representing a decrease of -74.08% compared to 2021. CLLS's yearly revenue for 2021 was $73.95M, representing an increase of 0% compared to 2020.
What is Cellectis’s quarterly revenue?
Cellectis's quarterly revenue for Q1 2024 was $4.53M, a 1500.00% increase from the previous quarter (Q4 2023), and a 3157.55% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $283K, a 82.58% increase from the previous quarter (Q3 2023), and a -98.23% decrease year-over-year (Q4 2022). CLLS's quarterly revenue for Q3 2023 was $155K, a -12.92% decrease from the previous quarter (Q2 2023), and a -28.57% decrease year-over-year (Q3 2022).
What is Cellectis’s revenue growth rate?
Cellectis's revenue growth rate for the last 3 years (2021-2023) was -98.98%, and for the last 5 years (2019-2023) was -95.03%.
What are Cellectis’s revenue streams?
Cellectis's revenue streams in c 22 are Therapeutics
What is Cellectis’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Cellectis was Therapeutics. This segment made a revenue of $25.72M, representing 100.00% of the company's total revenue.